Cardinal Health Inc. is exploring a potential sale of its nuclear medicine business as part of a larger review of its strategy and operations, according to people familiar with the matter.
The Dublin, Ohio-based drug distributor is working with advisers to scope out interest in the unit, said the people, who asked not to be identified because the matter isn’t public. Several private equity firms are mulling offers and the business could fetch a value of more than $1 billion in a sale, some of the people said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.